MXPA05006408A - Derivados deuterizados de catecolamina y medicamentos comprendiendo estos compuestos. - Google Patents

Derivados deuterizados de catecolamina y medicamentos comprendiendo estos compuestos.

Info

Publication number
MXPA05006408A
MXPA05006408A MXPA05006408A MXPA05006408A MXPA05006408A MX PA05006408 A MXPA05006408 A MX PA05006408A MX PA05006408 A MXPA05006408 A MX PA05006408A MX PA05006408 A MXPA05006408 A MX PA05006408A MX PA05006408 A MXPA05006408 A MX PA05006408A
Authority
MX
Mexico
Prior art keywords
compounds
medicaments
catecholamine derivatives
deuterated catecholamine
diseases
Prior art date
Application number
MXPA05006408A
Other languages
English (en)
Inventor
Rudolf-Giesbert Alken
Original Assignee
Bdd Berolina Drug Dev Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bdd Berolina Drug Dev Gmbh filed Critical Bdd Berolina Drug Dev Gmbh
Publication of MXPA05006408A publication Critical patent/MXPA05006408A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invencion se relaciona con derivados deuterizados de catecolamina y medicamentos comprendiendo estos compuestos. La invencion se relaciona ademas con el uso de derivados deuterizados de catecolamina, sus sales farmacologicamente compatibles y compuestos farmaceuticos conteniendo los compuestos referidos, tambien en combinacion con inhibidores de enzimas, para el tratamiento de enfermedades de deficiencia de dopamina relacionadas con el transporte perturbado de tirosina o la tirosina decarboxilasa perturbada y otras enfermedades.
MXPA05006408A 2002-12-19 2003-12-18 Derivados deuterizados de catecolamina y medicamentos comprendiendo estos compuestos. MXPA05006408A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10261807A DE10261807A1 (de) 2002-12-19 2002-12-19 Deuterierte Catecholaminderivate sowie diese Verbindungen enthaltende Arzneimittel
PCT/DE2003/004203 WO2004056724A1 (de) 2002-12-19 2003-12-18 Deuterierte catecholaminderivate sowie diese verbindungen enthaltende arzneimittel

Publications (1)

Publication Number Publication Date
MXPA05006408A true MXPA05006408A (es) 2006-03-08

Family

ID=32404400

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05006408A MXPA05006408A (es) 2002-12-19 2003-12-18 Derivados deuterizados de catecolamina y medicamentos comprendiendo estos compuestos.

Country Status (18)

Country Link
US (2) US8168820B2 (es)
EP (1) EP1613571B1 (es)
JP (5) JP2006510686A (es)
CN (1) CN100584807C (es)
AT (1) ATE451340T1 (es)
AU (1) AU2003289841B2 (es)
CA (1) CA2513088C (es)
DE (2) DE10261807A1 (es)
DK (1) DK1613571T3 (es)
EA (1) EA009258B1 (es)
ES (1) ES2337046T3 (es)
HK (1) HK1086548A1 (es)
IL (1) IL169203A (es)
MX (1) MXPA05006408A (es)
NZ (1) NZ541047A (es)
PL (1) PL219269B1 (es)
PT (1) PT1613571E (es)
WO (1) WO2004056724A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100360109B1 (ko) * 2000-12-19 2002-11-07 주식회사 포스코 미분을 재활용하는 분철광석의 유동층식 용융환원장치 및이를 이용한 용융환원방법
DE10261807A1 (de) 2002-12-19 2004-07-01 Turicum Drug Development Ag Deuterierte Catecholaminderivate sowie diese Verbindungen enthaltende Arzneimittel
CA2642593C (en) * 2006-02-17 2014-11-04 Birds Pharma Gmbh Berolina Innovative Research & Development Services Deuterated catecholamine derivatives and medicaments comprising said compounds
EP2727915B1 (en) * 2007-09-13 2016-04-13 Concert Pharmaceuticals Inc. Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof
US9763904B2 (en) 2013-02-05 2017-09-19 Teva Pharmaceuticals International Gmbh Position-specific asymmetric deuterium enriched catecholamine derivatives and medicaments comprising said compounds
ES2901752T3 (es) 2013-02-05 2022-03-23 Teva Pharmaceuticals Int Gmbh Derivados de catecolamina enriquecidos con deuterio asimétrico de posición específica y medicamentos que comprenden dichos compuestos
EP3611159B1 (en) * 2013-07-08 2023-01-25 Auspex Pharmaceuticals, Inc. Dihydroxyphenyl neurotransmitter compounds, compositions and methods
EP2918266A1 (en) 2014-03-11 2015-09-16 CDRD Berolina AB Composition comprising a dopamine agonist and an L-DOPA derivative for treating Parkinson's disease
BR112018007118A2 (pt) 2015-10-09 2018-12-11 Teva Pharmaceuticals Int Gmbh método para tratar um distúrbio de deficiência de dopamina, método para melhorar o tempo motor ativo sem discinesia num paciente com doença de parkinson, método para reduzir discinesia num indivíduo com um distúrbio de deficiência de dopamina, método para reduzir o tempo motor inativo num indivíduo com um distúrbio de deficiência de dopamina, método para reduzir flutuações de nível de dopamina estriatal num indivíduo com um distúrbio de deficiência de dopamina, método para reduzir discinesia num indivíduo com um distúrbio de deficiência de dopamina após um tratamento de longo prazo, composição farmacêutica e embalagem

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3699158A (en) * 1969-08-25 1972-10-17 Merck & Co Inc Selective deuteration of tyrosine, aspartic and glutamic acids
US3769424A (en) 1970-10-01 1973-10-30 Merck & Co Inc Composition and method of treating dopamine deficiency in brain tissue
DE2049115C3 (de) 1970-10-06 1981-07-30 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai, Tokyo Verwendung von Calcium-5-butylpicolinat und/oder Calcium-5-pentylpicolinat bei der Bekämpfung des Parkinsonismus mit 3-(3,4-Dihydroxyphenyl)-L-alanin (L-Dopa)
US4663349A (en) 1985-12-30 1987-05-05 Merck & Co., Inc. Rectally absorbable form of L-dopa
ES2042520T3 (es) 1986-06-10 1993-12-16 Chiesi Farma Spa Composiciones farmaceuticas que contienen el ester metilico de levodopa, preparacion y aplicaciones terapeuticas del mismo.
JP2718504B2 (ja) * 1988-02-22 1998-02-25 アローンサクル シャオバニー 中枢神経系疾患治療法及びアルツハイマー病診断法
IT1226902B (it) * 1988-07-12 1991-02-21 Mini Ricerca Scient Tecnolog Processo per la sintesi del levodopa
US5354885A (en) * 1992-12-24 1994-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Process for preparing ethyl ester of L-DOPA
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
IL119417A (en) * 1996-10-13 2003-02-12 Moshe Kushnir Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease
JP4261049B2 (ja) * 1997-10-08 2009-04-30 アイソテクニカ インコーポレイテッド 重水素化シクロスポリンアナログおよび免疫調節剤としてのそれらの使用
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
NO309305B1 (no) * 1999-02-19 2001-01-15 Norsk Hydro As Anvendelse av benzaldehydderivater ved fremstilling av farmasöytiske preparater for forebygging og/eller behandling av kreft, samt visse nye benzaldehydderivater
DK1104760T3 (da) * 1999-12-03 2003-06-30 Pfizer Prod Inc Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler
JP2001203263A (ja) 2000-01-20 2001-07-27 Hitachi Ltd 半導体集積回路装置の製造方法および半導体集積回路装置
JP2002097137A (ja) 2000-07-19 2002-04-02 Junichi Sudo パーキンソン病の予防および／または治療剤
DE10123129A1 (de) 2001-05-02 2002-11-14 Berolina Drug Dev Ab Svedala Deuterierte 3-Piperidinopropiophenone sowie diese Verbindungen enthaltende Arzneimittel
DE10261807A1 (de) 2002-12-19 2004-07-01 Turicum Drug Development Ag Deuterierte Catecholaminderivate sowie diese Verbindungen enthaltende Arzneimittel

Also Published As

Publication number Publication date
EP1613571B1 (de) 2009-12-09
NZ541047A (en) 2008-09-26
IL169203A (en) 2012-05-31
USRE46629E1 (en) 2017-12-12
JP2006510686A (ja) 2006-03-30
JP2012087124A (ja) 2012-05-10
DK1613571T3 (da) 2010-04-12
PL219269B1 (pl) 2015-04-30
DE10261807A1 (de) 2004-07-01
CA2513088C (en) 2012-03-06
EA009258B1 (ru) 2007-12-28
EA200500958A1 (ru) 2006-02-24
ATE451340T1 (de) 2009-12-15
HK1086548A1 (en) 2006-09-22
WO2004056724A1 (de) 2004-07-08
JP2015178537A (ja) 2015-10-08
CN1738782A (zh) 2006-02-22
EP1613571A1 (de) 2006-01-11
CA2513088A1 (en) 2004-07-08
DE50312224D1 (de) 2010-01-21
JP2018193356A (ja) 2018-12-06
AU2003289841A1 (en) 2004-07-14
PT1613571E (pt) 2010-02-10
PL377584A1 (pl) 2006-02-06
US20060135615A1 (en) 2006-06-22
AU2003289841B2 (en) 2010-01-28
CN100584807C (zh) 2010-01-27
US8168820B2 (en) 2012-05-01
JP2015212287A (ja) 2015-11-26
ES2337046T3 (es) 2010-04-20

Similar Documents

Publication Publication Date Title
UA97795C2 (uk) Дейтеровані похідні катехоламіну і медикаменти, що містять згадані сполуки
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
MY143466A (en) Inhibitors of tyrosine kinases
TW200505423A (en) Combination, kit and pharmaceutical composition for treatment of parkinson's disease
HK1086548A1 (en) Deuterated catecholamine derivatives and medicaments comprising said compounds
IL181987A0 (en) Diaminotriazole derivatives and pharmaceutical compositions containing the same
MY143407A (en) Indazole derivatives as inhibitors of hormone sensitive lipase
IL184898A0 (en) Pyrrolopyrimidine derivatives and pharmaceutical compositions containing the same
NO20052888L (no) Diamintriazoler anvendelige som inhibitorer av proteinkinaser
EP1485381B8 (en) Azolylaminoazine as inhibitors of protein kinases
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
GEP20094845B (en) Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
IL161154A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
EP1562897A4 (en) PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER
AU2003218215A1 (en) Azolylaminoazines as inhibitors of protein kinases
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
DE60323765D1 (de) Inhibitoren der 17 beta-hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten
RS44204A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2004016741A3 (en) Prenylation inhibitors containing dimethyl-cyclobutane and methods of their synthesis and use
RS44304A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
PT1572686E (pt) Derivados de amida do ácido antranílico e suas utilizações farmacêuticas
WO2004056306A3 (de) Verwendung von l-dopa, seiner derivate und diese verbindungen enthaltender arzneimittel zur prophylaxe psychotischer erkrankungen
MY137288A (en) New process for the synthesis of n-[(s)-1-ethoxycarbonylbutyl]-(s)-alanine and application in the synthesis of perindopril
AU2003301174A8 (en) Liposomal analgesic formulation and use

Legal Events

Date Code Title Description
FG Grant or registration